Evidence map›Paper›PMID 39827439›Full record

ArticleDrugs & aging2025

How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.

Lauren M Fasth, Casey J Kelley, Cathleen Colón-Emeric, Ariel R Green, Carolyn T Thorpe, Meredith Gilliam, Jennifer L Lund, Laura C Hanson, Joshua D Niznik

Abstract read
In one paragraph

Article in Drugs & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Navigating Medication Risk in the ED: Communication Preferences of Older Adults Regarding Deprescribing.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2026
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lauren M FasthDivision of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Casey J KelleyCenter for Aging and Health, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Cathleen Colón-EmericDivision of Geriatrics, Duke University School of Medicine, Durham, NC, USA.
Ariel R GreenDivision of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Carolyn T ThorpeDivision of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Meredith GilliamCenter for Aging and Health, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jennifer L LundDepartment of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA.
Laura C HansonCenter for Aging and Health, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joshua D NiznikDivision of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Jdniznik@email.unc.edu.ORCID 0000-0003-1466-5751

Funding

Deprescribing Bisphosphonates in Older Nursing Home Residents with DementiaK08AG071794 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NIZNIK, JOSHUA DAVID · 2021 to 2025
$724k
NIA NIH HHS K08 AG071794NIA NIH HHS K08AG071794
6 · The paper itself

Abstract

backgroundPreventive medications are potential targets for deprescribing in older adults with dementia as goals of care change from preventive to palliative. Yet, prescribers lack communication guidance to address deprescribing.

objectiveUsing bisphosphonates as a case example, we sought to characterize and compare communication preferences of prescribers and family/informal caregivers regarding deprescribing.

methodsWe conducted 23 semi-structured interviews with prescribers (12) and caregivers (11) of older adults with Alzheimer's disease or related dementias (ADRD). Prescribers and caregivers were asked to provide their impressions of seven conversation starters for discussing deprescribing, focusing on a case example using bisphosphonates. These phrases focused on topics including life expectancy, treatment burden, adverse effects, and costs. We used a qualitative framework analysis to identify relevant themes as prescribers and caregivers discussed their general perceptions of the potential benefits and harms of bisphosphonates and experiences with deprescribing.

resultsAmong prescribers, there were ten physicians and two nurse practitioners; most (nine) female and white. Among caregivers, eight were female, seven were white, and five were Latino/a. For both prescribers and caregivers, preferred conversation starters initiated a risk versus benefit discussion, emphasizing medication adverse effects and patient-specific factors, such as functional status and indication for treatment. While prescribers emphasized discussing common medication adverse effects, caregivers noted the importance of knowing a medication's potential impact on ADRD. The least preferred conversation starter for deprescribing among both groups focused on the extra effort and cost of continuing bisphosphonates. Discordance between caregivers and prescribers were identified in several phrases; notably, caregivers disliked statements that introduced discussions of prognosis and life expectancy.

conclusionsDeprescribing conversations may be best perceived by caregivers when introduced with a discussion of a medication's adverse effects and potential impact on cognition. In addition, deprescribing conversations should be tailored to patient-specific factors, including functional status, goals of care, and the role of their caregiver in medical decision-making. Avoiding discussions of medication cost, pill burden, and life expectancy may help reassure the caregiver that deprescribing is a form of medication optimization and not a withdrawal of care.

Indexed as

CaregiversDementiaDeprescriptionsAgedAged, 80 and overDiphosphonatesFemaleHumansMaleMiddle AgedPhysiciansQualitative ResearchDiphosphonates

Identifiers

PMID39827439
PMCPMC11848725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.